Computational Comparison of Two New Fusion Proteins for Multiple Sclerosis

Overview

Journal Res Pharm Sci

Specialty Chemistry

Date 2018 Oct 2

PMID 30271441

Citations 2

Authors

Nasrin Payab

Karim Mahnam

Mostafa Shakhsi-Niaei

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS), as one of the human autoimmune diseases, demyelinates the neurons of the central nervous system (CNS). Activation of the T cells which target the CNS antigens is the first autoimmune event in MS. Myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) are two proteins of the myelin sheath and have been shown to be among the high antigens contributing to the pathogenesis of MS. Production of the drugs with high specificity for the immune system diseases is a concern for various researchers. Therefore, tolerogenic vaccines are considered as a new strategy for the treatment of MS by presenting specific antigens. This study aimed to design and compare two fusion proteins by a combination of two neuroantigens linked to interleukin-16 (IL-16) (MOG-Linker-MBP-IL16 and MBP-Linker-MOG-IL16) as vaccines for MS. In this study, at first two models MOG (aa 11-30) linked to MBP (aa 13-32) was made by Modeler 9.10 and simulated for 20 ns via Gromacs 5.1.1 package. Then simulated antigen domains connected to the N-terminal domain of IL-16 and obtained structures simulated for 50 ns. The results revealed that both constructs had stable structures and the linker could keep two antigenic fragments separate enough, preventing undesired interactions. While MOG-Linker-MBP-IL16 showed better solubility, more accessible surface areas, more flexibility of its IL-16 domain, and better functionality of its IL-16 domain as well as more specific cleavage of its related epitopes after endocytosis lead to a better presentation of its antigenic property.

Citing Articles

Computational design of newly engineered DARPins as HER2 receptor inhibitors for breast cancer treatment.

Isfahani M, Mahnam K, Seyedhosseini-Ghaheh H, Mohammad Sadeghi H, Khanahmad H, Akbari V Res Pharm Sci. 2024; 18(6):626-637.

PMID: 39005564 PMC: 11246109. DOI: 10.4103/1735-5362.389950.

Design and molecular dynamic simulation of a new double-epitope tolerogenic protein as a potential vaccine for multiple sclerosis disease.

Banisharif-Dehkordi F, Mobini-Dehkordi M, Shakhsi-Niaei M, Mahnam K Res Pharm Sci. 2019; 14(1):20-26.

PMID: 30936929 PMC: 6407332. DOI: 10.4103/1735-5362.251849.

References

Zambrano R, Jamroz M, Szczasiuk A, Pujols J, Kmiecik S, Ventura S . AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures. Nucleic Acids Res. 2015; 43(W1):W306-13. PMC: 4489226. DOI: 10.1093/nar/gkv359. View

Basu S, Sen S . Do homologous thermophilic-mesophilic proteins exhibit similar structures and dynamics at optimal growth temperatures? A molecular dynamics simulation study. J Chem Inf Model. 2012; 53(2):423-34. DOI: 10.1021/ci300474h. View

Ikai A . Thermostability and aliphatic index of globular proteins. J Biochem. 1980; 88(6):1895-8. View

Idicula-Thomas S, Balaji P . Understanding the relationship between the primary structure of proteins and its propensity to be soluble on overexpression in Escherichia coli. Protein Sci. 2005; 14(3):582-92. PMC: 2279285. DOI: 10.1110/ps.041009005. View

Mansourian M, Madadkar-Sobhani A, Mahnam K, Fassihi A, Saghaie L . Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor. J Mol Model. 2012; 18(9):4309-24. DOI: 10.1007/s00894-012-1427-y. View

Baker N, Sept D, Joseph S, Holst M, McCammon J . Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci U S A. 2001; 98(18):10037-41. PMC: 56910. DOI: 10.1073/pnas.181342398. View

Dolinsky T, Nielsen J, McCammon J, Baker N . PDB2PQR: an automated pipeline for the setup of Poisson-Boltzmann electrostatics calculations. Nucleic Acids Res. 2004; 32(Web Server issue):W665-7. PMC: 441519. DOI: 10.1093/nar/gkh381. View

Clements C, Reid H, Beddoe T, Tynan F, Perugini M, Johns T . The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci U S A. 2003; 100(19):11059-64. PMC: 196926. DOI: 10.1073/pnas.1833158100. View

Colovos C, Yeates T . Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993; 2(9):1511-9. PMC: 2142462. DOI: 10.1002/pro.5560020916. View

10.

Chothia C, Lesk A . The relation between the divergence of sequence and structure in proteins. EMBO J. 1986; 5(4):823-6. PMC: 1166865. DOI: 10.1002/j.1460-2075.1986.tb04288.x. View

11.

Eisenberg D, Luthy R, Bowie J . VERIFY3D: assessment of protein models with three-dimensional profiles. Methods Enzymol. 1997; 277:396-404. DOI: 10.1016/s0076-6879(97)77022-8. View

12.

Kremer D, Kury P, Dutta R . Promoting remyelination in multiple sclerosis: current drugs and future prospects. Mult Scler. 2015; 21(5):541-9. DOI: 10.1177/1352458514566419. View

13.

Dargahi N, Katsara M, Tselios T, Androutsou M, de Courten M, Matsoukas J . Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017; 7(7). PMC: 5532591. DOI: 10.3390/brainsci7070078. View

14.

Tzakos A, Fuchs P, van Nuland N, Troganis A, Tselios T, Deraos S . NMR and molecular dynamics studies of an autoimmune myelin basic protein peptide and its antagonist: structural implications for the MHC II (I-Au)-peptide complex from docking calculations. Eur J Biochem. 2004; 271(16):3399-413. DOI: 10.1111/j.1432-1033.2004.04274.x. View

15.

Mannie M, Blanchfield J, Touhidul Islam S, Abbott D . Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol. 2012; 3:255. PMC: 3422719. DOI: 10.3389/fimmu.2012.00255. View

16.

Mannie M, Abbott D . A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis. J Immunol. 2007; 179(3):1458-65. DOI: 10.4049/jimmunol.179.3.1458. View

17.

Hoze E, Tsaban L, Maman Y, Louzoun Y . Predictor for the effect of amino acid composition on CD4+ T cell epitopes preprocessing. J Immunol Methods. 2013; 391(1-2):163-73. PMC: 3646362. DOI: 10.1016/j.jim.2013.02.006. View

18.

Stuart A, Fiser A, Sanchez R, Melo F, Sali A . Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct. 2000; 29:291-325. DOI: 10.1146/annurev.biophys.29.1.291. View

19.

Storch M, Stefferl A, Brehm U, Weissert R, Wallstrom E, Kerschensteiner M . Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998; 8(4):681-94. PMC: 8098227. DOI: 10.1111/j.1750-3639.1998.tb00194.x. View

20.

Mannie M, Curtis 2nd A . Tolerogenic vaccines for Multiple sclerosis. Hum Vaccin Immunother. 2013; 9(5):1032-8. PMC: 3899137. DOI: 10.4161/hv.23685. View